Abstract
To analyze the clinical efficacy of azithromycin in the treatment of pediatric Mycoplasma pneumoniae pneumonia and its impact on platelet count and D-dimer levels. A comparison was made between the two groups regarding clinical treatment effects, recovery status, levels of blood indicators [C-reactive protein (CRP), white blood cell count (WBC), platelet count (PLT), D-dimer (D-D)], and the occurrence of adverse reactions. The control group received conventional symptomatic treatment, while the case group received both conventional treatment and azithromycin. ① Clinical treatment effects: The total effective rate of treatment in the control group was 84.21%, while it was significantly higher at 96.83% in the case group (P < 0.05). ② Recovery status: After treatment, the case group exhibited significantly shorter durations for fever clearance, cough disappearance, rale disappearance, resolution of chest radiographic shadows, and hospital stay compared to the control group (P < 0.05). ③ Blood indicator levels: After treatment, the levels of C-reactive protein (CRP), white blood cell count (WBC), platelet count (PLT), and D-dimer (D-D) were significantly lower in the case group than in the control group, indicating an improvement in the inflammatory response and blood clotting status. Addition of azithromycin to conventional symptomatic treatment significantly improves the efficacy of Mycoplasma pneumoniae pneumonia treatment in children, reduces inflammatory response, improves blood circulation, further promotes recovery without a substantial increase in related adverse reactions, suggesting its relatively high safety in clinical application and advocating for its clinical promotion.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call